logo
Plus   Neg
Share
Email

Array BioPharma Says BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints

Array BioPharma Inc. (ARRY) reported positive results from the interim analysis of the Phase 3 BEACON CRC trial evaluating the combination of BRAFTOVI or encorafenib, a BRAF inhibitor, MEKTOVI or binimetinib, a MEK inhibitor, and ERBITUX or cetuximab, an anti-EGFR antibody or BRAFTOVI Triplet, in patients with BRAFV600E-mutant metastatic colorectal cancer or mCRC, following one or two prior lines of therapy.

The company stated that the trial met both primary endpoints of confirmed objective response rate or ORR, as assessed by Blinded Independent Central Review or BICR, and overall survival or OS.

The company plans to submit these results of the BEACON CRC trial for marketing approval in the second half of 2019.

The triplet combination of BRAFTOVI, MEKTOVI and ERBITUX for the treatment of patients with BRAFV600E-mutant mCRC is investigational and not approved by the FDA.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. is taking necessary precautions including Covid-19 testing for those employees returning to work at its headquarters in Silicon Valley, Bloomberg reported citing people familiar with the process. The company, which opened its main Apple Park office in May bringing back some hardware and software engineers, plans the gradual reopening of the building keeping the coronavirus safeguards. A U.S. appeals court has blocked the sales of Bayer AG's dicamba-based Xtendimax in the United States. The three-judge panel in the U.S. Court of Appeals for the Ninth Circuit ruled that the US Environmental Protection Agency (EPA) overstated the protections and substantially understated or ignored the risks related to the use of dicamba-based herbicides. Tesla Chief Executive Officer Elon Musk has called for a breakup of Amazon after the online retail giant refused to publish an upcoming book about COVID-19. Writer Alex Berenson said on Twitter that Amazon refused to publish his booklet about the coronavirus as it did not comply with the company's guidelines. Berenson is a former New York Times reporter.
Follow RTT